The Massey Cancer Center is a matrix center located at Virginia Commonwealth University, whose mission is to provide comprehensive, cancer-focused basic, clinical, and population research, clinical services, outreach, and education to the State of Virginia and the nation. The major goals of the Cancer Center are 1) to facilitate high-quality basic, clinical, and population-based research focused on the cancer problem and 2) to promote interdisciplinary and transdisciplinary collaborations among the scientific programs and members of the Cancer Center and translate findings into more effective interventions for cancer prevention and treatment. During the last project period, NCI annual total cost funding for Cancer Center members increased from $15,777,576 to $18,011,992, and total peer-reviewed funding from $33,125,861 to $38,016,473. During this period we expanded translational and clinical research activities, increased high impact cancer-focused research, and increased transdisciplinary research. Major goals for the next grant period are to further enhance our translational-clinical research activities, increase the depth and scope of collaborative programmatic research, and intensify our research focus on the problems of health care disparities among racial, ethnic, and other underserved populations. Research activities of the Massey Cancer Center are earned out through five research programs: Cancer Cell Signaling, Cancer Molecular Genetics, Cancer Prevention and Control, Developmental Therapeutics, and Radiation Biology and Oncology. The translational programs include both basic research and either clinical/translational or applied population research so as to facilitate transdisciplinary collaboration and rapid implementation and dissemination of research findings. In order to provide support for the predominantly peer-reviewed research base of the scientific programs, the Cancer Center supports nine shared resources: Clinical Research; Biostatistics; Flow Cytometry; Biologic Macromolecule; Behavioral Measurement; Structural Biology; Transgenic/Knockout Mouse; Cancer Research Informatics and Services; and Tissue and Data Acquisition and Analysis. This application requests continuation of CCSG funding to provide partial support for these shared resources as well as for senior leadership, program leadership, administration, staff investigators, protocol-specific research, program planning and evaluation, protocol review and monitoring, data and safety monitoring, and developmental funds, which are necessary to facilitate and stimulate transdisciplinary cancer research and translation throughout the Cancer Center.

Public Health Relevance

The mission of MCC is to serve Virginia and the nation as an internationally recognized comprehensive research and treatment center dedicated to improving the quality of human life by eliminating suffering and death through development and delivery of more effective means for the detection, treatment, prevention, control and ultimate cure of cancer. The core of this mission is to facilitate interdisciplinary and transdisciplinary cancer research so as to harness the considerable intellectual talent and scientific resources of VCU and focus them on solving the nation's cancer problem.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016059-35S3
Application #
9338029
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Program Officer
Ptak, Krzysztof
Project Start
1978-12-01
Project End
2017-04-30
Budget Start
2016-08-29
Budget End
2017-04-30
Support Year
35
Fiscal Year
2016
Total Cost
$39,980
Indirect Cost
$13,763
Name
Virginia Commonwealth University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Li, Xiaojiaoyang; Liu, Runping; Huang, Zhiming et al. (2018) Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans. Hepatology 68:599-615
Durant, Stephen T; Zheng, Li; Wang, Yingchun et al. (2018) The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv 4:eaat1719
Damle, S R; Martin, R K; Cockburn, C L et al. (2018) ADAM10 and Notch1 on murine dendritic cells control the development of type 2 immunity and IgE production. Allergy 73:125-136
Wang, Feng; Li, Hongyan; Markovsky, Ela et al. (2018) Pazopanib radio-sensitization of human sarcoma tumors. Oncotarget 9:9311-9324
Stokes, Nancy A; Stanciu, Cristina E; Brocato, Emily R et al. (2018) Simplification of complex DNA profiles using front end cell separation and probabilistic modeling. Forensic Sci Int Genet 36:205-212
Poklepovic, Andrew; Qu, Yuesheng; Dickinson, Molly et al. (2018) Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. Cardiooncology 4:
Karlin, Jeremy; Allen, Jasmine; Ahmad, Syed F et al. (2018) Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice. Mol Cancer Ther 17:1637-1647
Robertson, Chadia L; Mendoza, Rachel G; Jariwala, Nidhi et al. (2018) Astrocyte Elevated Gene-1 Regulates Macrophage Activation in Hepatocellular Carcinogenesis. Cancer Res 78:6436-6446
Kazarian, Elizabeth; Son, HyunYoung; Sapao, Paulene et al. (2018) SPAG17 Is Required for Male Germ Cell Differentiation and Fertility. Int J Mol Sci 19:
Farrell, Nicholas P; Gorle, Anil K; Peterson, Erica J et al. (2018) Metalloglycomics. Met Ions Life Sci 18:

Showing the most recent 10 out of 586 publications